Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres.

Monika KohliKinjal PatelZofia MacMahonRadha RamachandranMartin A CrookTimothy M Reynolds Anthony S Wierzbicki

Published in: International journal of clinical practice (2017)

This study suggests that PCSK-9 inhibitors are effective but that prescriptions should not be changed to long-term delivery until patients have been reviewed and shown to be adherent.

Keyphrases

end stage renal disease
low density lipoprotein
primary care
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
prognostic factors
patient reported outcomes
fatty acid
binding protein
patient reported